Study of an experimental antibody for multiple system atrophy
Part of Brain & nervous system clinical trials.
This study tests a new antibody drug that targets a protein linked to multiple system atrophy (MSA). It aims to see if the drug is safe and may slow the disease, for people recently diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 75 years old.
- You have been diagnosed with multiple system atrophy (MSA), either probable or possible.
- Your symptoms started within the last 2 years.
- Your condition has been stable, without sudden changes, for at least 4 weeks.
- You do not have significant memory or thinking problems.
- You are not pregnant or breastfeeding and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
This study looks at how the body handles blood sugar (insulin resistance) in people with multiple system atrophy (MSA). Results may help doctors understand the disease better and explore new ways to monitor or treat it.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This trial tests whether a medication called butylphthalide can help slow or improve symptoms of multiple system atrophy (MSA), a rare neurological condition that affects movement, balance, and automatic body functions. The study will measure how well the drug works and how safe it is for patients.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.